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Distribution of Di(2-ethylhexyl) Phthalate
and Products in Blood and Blood
Components
by G. Rock,*t Rosalind S. Labow,* and Monika Tocchi*
In order to impart flexibility, plastic medical devices incorporate liquid plasticizers into their structure. Data
from several laboratories, includingours, have shownthatthese compounds leach from blood bags andtubing
during collection of blood, storage of various blood components and during kidney dialysis and cell and
plasmaapheresis procedures. Aftertheplasticizerdi(2-ethylhexyl) phthalateleachesfrompoly(vinylchloride)
blood packs, it is converted by a plasma enzyme to a more toxic metabolite, mono(2-ethylhexyl) phthalate.
Blood fractionation products from outdated plasma contain mono(2-ethylhexyl) phthalate, the highest level
being found in normal serum albumin.
Recently, we have reported that di(2-ethylhexyl) phthalate actually binds to the red blood cell membrane
and reduces its osmotic fragility. Current methods of red cell storage, which permit utilization up to 35
days after collection, are not possible without this membrane stabilization. Platelets are now stored for 5
days in the Fenwal PL 732 polyolefin bag. Although stated to be essentially free of liquid plasticizers, a
significant level of leaching from this bag into the extracts of stored platelet concentrates was observed.
Introduction
The development of flexible plastic bags and multiple
pack systems has revolutionized blood banking, permit-
ting the rapid and easy preparation ofblood components
for therapeutic use. However, for some time it has been
known that the plasticizer di(2-ethylhexyl) phthalate
(DEHP), which is added to poly(vinyl chloride) (PVC)
plastics to increase flexibility, can leach from the plastic
during exposure to blood and blood components (1-6).
PVC plastic is used in a great variety ofmedical devices,
such as tubing for whole blood collection, bags for collec-
tion and storage ofred cells, platelet concentrates (PC),
or plasma, hemodialysis setups, tubing for intravenous
injections, cytapheresis, plasma exchange and plasma-
pheresis.
DEHP plasticizer accounts for 30 to 40% ofthe weight
ofthe formulated material and exists in the PVC matrix
with a loose attachment to the resin in a semisolid or
gellike structure. This loose arrangement is responsible
for the leachability of the plasticizer upon contact with
biological fluids. In 1967, Guess et al. (7) first reported
the presence of DEHP as a contaminant ofhuman blood
stored in PVC bags. Subsequent work has demonstrated
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that DEHPaccumulatesinstoredwholeblood, inplatelet
concentrates (PC) (3), in cryoprecipitates (8), and in
plasma derivatives (9) where there is a particular asso-
ciation with albumin.
Anearlierpublication had indicated thatplatelets were
responsible for the leaching and subsequent plasma ac-
cumulation of DEHP However, work in our laboratory
demonstrated that a plasma protein which is not asso-
ciated with platelets is responsible for the accumulation
ofDEHP, andthatthe DEHPis, forthe most part, bound
to plasma proteins (6). In any blood component where
DEHP is found, the hydrolysis product mono(2-ethyl-
hexyl) phthalate (MEHP), is alsofound to alesserextent.
The accumulation of MEHP was shown to be a direct
result of the hydrolysis of DEHP by a plasma enzyme
(6). This enzyme cofractionates with albumin, and some
commercialpreparations ofnormal serumalbumin (NSA)
contain significant amounts of both DEHP and MEHP
(9). MEHP accumulation is of concern because MEHP
has been shown to be 20 times more toxic than DEHP
in rats (10).
The recent introduction ofnon-DEHP-containing bags
for blood component production and storage was greeted
with enthusiasm, since it was reasoned that DEHP, and
therefore MEHP, exposure would be greatly reduced;
however, PVC bags are still the most widely used for the
collection and storage ofred cell concentrates (RCC). We
have recently found that DEHP binds to the red cellROCK, LABOW, AND TOCCHI
membrane and decreases its osmotic fragility (11). When
RCC are stored beyond 21 days inthe absence ofDEHP
considerable hemolysis occurs. Further, the in vivo sur-
vivalisdecreased. Thus, thelong-term (beyond 21 days)
storage of RCC is not possible without the stabilizing
effect of DEHP.
Recently, apolyolefinbag, the FenwalPL 732, hasbeen
introduced forthe storage ofplatelets. This has extended
the viability of the platelets from 3 to 5 days. Phospho-
lipase A2 in platelet membranes is inhibited by DEHP
(12). Perhaps the high level of DEHP which leaches out
of the PVC bag is one of the causes of the platelet dys-
function found after three days of storage in the PVC
bag; however, there may be another factor. Although the
product is stated by the manufacturer to be essentially
free of liquid plasticizers, we have recently found that
there is a significant level of leaching of compounds into
PC, platelet rich plasma (PRP), or platelet poor plasma
(PPP) when these fractions are stored in the PL 732 bag
(13). The function of platelets is better when stored in
thesebags, butaberrant morphological changeshave also
been observed (14).
Since compounds are leachingfrom PVC and polyolefin
bags, and storage in. these bags vastly improves the
length of storage time of RCC and platelets, it would be
extremely valuable to understand the mechanism ofthis
increased stability, and fully define the biochemistry of
interaction of the leachable materials with the RC and
platelet membranes.
Results
One ofthe earliest studies done in our laboratory was
to establish which blood component was responsible for
DEHP leaching during storage of blood in PVC bags.
After exposure to PVC plastics, DEHP levels in whole
blood steadilyincreased for upto4weeks storage inPVC
bags at 4°C (Fig. 1). Although it was previously thought
(1) that platelets played an important role in the accu-
mulation of DEHP in plasma, 72-hr PC, PRP, and PPP
storage at 22°C showed similar concentrations of DEHP
when corrections were made for volume differences (6)
(Table 1). When plasma (which contained DEHP) was
kept in glass, MEHP appeared with the concomitant
disappearance ofDEHP. Not all ofthe DEHP there orig-
inally was accounted for by MEHP accumulation. This
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FIGURE 1. Accumulation of DEHP and MEHP during storage of
whole blood in PVC bags at 40 C.
discrepancy was shown to be the result of the presence
of other metabolites of MEHP, such as 2-ethylhexanol,
2-ethylhexanone, 2-ethylhexanoic acid, and some phthalic
acid. These metabolites were identified by examination
ofthe urine after 14C-MEHP was administered orally to
rats. Morethan80%ofthedoseofradioactivity wasfound
in the urine within 24 hr ofingestion (10). The liver was
shown to be the major site of deposition, as well as the
bladder and kidney, although the levels in the latter two
tissues were probably high due to the excretory role
played by these organs.
TheaccumulationofDEHPinstoredbloodisofconcern
for patients who receive multiple transfusions of blood
products, although the long-term harmful side effects of
this exposure have not been established. In animals the
acute toxicity of phthalate esters is low with oral LD50
values in the range of20 to 30 g/kg in mice and rats (15).
Intravenous LD50 values in rats are in the range of 200
to 300 mg/kg. DEHP has been shown to elicit specific
toxicological effects on the liver following oral adminis-
tration to rats (15), with ultrastructural and biochemical
changes having been observed (15). Recently, a study at
Table 1. Accumulation of DEHP and MEHP during storage at 22°C in various blood components.
DEHP/MEHP concentration after various storage times, ,ug/mL
Sample Initial volume, mL 0 24 hr 48 hr 72 hr
DEHP
PC 30 76± 7* 302±22 491 ±36
PRP 120 5 ± 2 34 ± 2 136 ± 4 181 ± 7
PPP 90 52 ± 2 197 ± 28 285 ± 40
MEHP
PC 30 15.0 ± 7.7 28.5 ± 1.6 76.1 ± 11.5
PRP 120 2.7 ± 0.8 5.9 ± 0.5 13.2 ± 1.2 31.0 ± 0.9
PPP 90 8.5 ± 0.9 20.0 ± 0.8 53.6 ± 3.9
End Table 1, Chapter 41
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the National Institutes of Health documented carcino-
genicity in rats and mice following oral administration of
large doses ofDEHP (16). Atrophy ofthe testis and ces-
sation of spermatogenesis have also been observed (15).
At the cellular level, DEHP is lethal for chick embryo
beating heart at a concentration of 4 pRg/mL (15). It is
highly toxic to mice fibroblasts in culture and causes
significant growth inhibition ofhuman diploid fibroblasts
in tissue culture (15).
These toxicity figures are not necessarily applicable to
blood and blood products; however, some typical amounts
ofDEHP exposure can be calculated. Based on rates of
leachingofDEHPof0.25mg/100mL/dayintowholeblood
stored at 40C (15), a 70-kg man given a single exchange
transfusion (3 L) of whole blood which has been stored
for 3 weeks at 40C would receive approximately 250 mg
DEHP, a dose equivalent to 3.6 mg/kg. Administration
ofvarious products to the "multi-transfused" patient re-
sults in average exposures to DEHP in the range of 1
mg per patient per day for whole blood (9), 0.6 mg per
patient per day for packed cells, and 3 mg per patient
per day for platelet concentrates. -
Hemophiliacs are one ofthe patient populations at risk
of considerable exposure, since they may receive many
transfusions ofblood products in a short period oftime.
Each cryoprecipitate contains approximately 20 ,ug/mL
of DEHP (17). The higher purity VIIIC concentrates
contain no DEHP and < 1 ,ug/mL MEHP (9). In a study
carried out at the Ottawa Centre, DEHP blood levels
were measured before and after infusion with cryopre-
cipitate into hemophiliac patients, and all of the DEHP
was cleared from the blood 10 min after infusion. Al-
though constant exposure to DEHP can result in the
induction of liver microsomal enzymes along with other
structural changes (15), all of our patients had normal
liver function.
Patients undergoingrenal dialysis have alsobeen stud-
ied as another high risk group. Several reports (18) have
demonstrated the extraction of 1.5 mg of DEHP from
hemodialysis tubing into the blood of a patient dialyzed
for 5 hr (19), with the levels peaking within the first few
minutes of hemodialysis. The MEHP concentration in-
creases gradually. When we carried out a similar study,
we measured pre- and post-dialysis whole blood levels of
DEHP in a series of 14 patients. The concentration of
DEHP ranged from 1 to 14.5 ,ug/mL. MEHP was de-
tected in seven of these patients before dialysis, while
thepost-dialysisbloodsamplesofall 14patientscontained
0.2-4 ,ug/mL ofthe compound. The high levels ofDEHP
in the predialysis samples in some patients were found
to be due to leaching from the Terumo AVF extension
set. Our study showed that DEHP leached from the ar-
tificial kidney; it was detectable in blood after only one
passage through the dialysis machine. However, DEHP
wasrapidlyremoved fromthecirculatory system asnone
was found in blood after 15 min. MEHP also appeared
in the blood after one passage through the artificial kid-
ney, indicating that DEHP was rapidly converted to
MEHP, thelevelofwhichremained elevated after 15min.
If daily plasma exchange is required for 8 days, as is
often the case, the total short-term exposure would be
29 mg DEHE Exposure approaching this value could
occurforcytopheresis orplasmapheresis donors, thereby
putting the normal donor population at risk.
WheneverDEHPispresent, MEHPalso appears. The
characteristics and site ofthis metabolic conversion were
studied in our Centre. One site for this reaction to occur
wasshowntobeplasma. Asolubleenzymewhichconverts
DEHP to MEHP was partially purified by high speed
centrifugation of PPP (20). The enzyme responsible for
the conversion has a pH optimum of 7.2 and a molecular
weight of50,000 to 100,000; it appears to exist in a com-
plex with the oxidation system that further degrades
MEHP In its partially purified state, Mg2e and ATP
stimulate the activity, whereas adenine (0.13 mM) and
detergents inhibit it (Fig. 2). The enzyme can be freed
of95% oftheplasmaalbuminbypassagethroughanAffi-
gel Blue column; however, polyacrylamide gel electropho-
resis of the partially purified enzyme still indicates a
significant contamination by albumin.
A comparison of whole blood stored in citrate-phos-
phate-dextrose (CPD)-adenine blood packs shows that
the presence ofadenine actually causes a decrease in the
amount of DEHP converted to MEHP; however, the use
ofCPD-adenine packstoincrease the storage life ofRCC
past 21 days also means a higher final level of DEHP,
since the concentration ofDEHP gradually increases up
to 46 days when whole blood is stored at 40C (21).
Sinceplasmacontainstheenzymesystemfortheleach-
ing and conversion ofDEHP to MEHP and because this
systemisincreasinglyactive athighertemperatures, the
conditions used forthe storage andtransport ofoutdated
plasma used for fractionation are of great significance.
Low levels ofDEHP contamination have been found in a
number of Cohn fractions including fibrinogen, gamma-
globulin, and albumin (22). Low levels of MEHP were
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Table 2. DEHP and MEHP levels in blood products from three different companies.
Phthalate acid ester concentration, pug/mLa
Company A Company B Comapny C
Blood product MEHP DEHP MEHP DEHP MEHP DEHP
NSA (5%) 1 ± 0 0 Trace 0 N/A N/A
NSA (25%) 10 ± 1 0 13 ± 10 0 330 ± 48 0
PPF (5%) 5 ± 1 0 Trace 0 N/A N/A
Factor VIII 1 ± 1 0 0 0 N/A N/A
Factor IX 0 0 0 0 3 ± 2 23 ± 16
Immune serum globulin 0 0 0 0 0 0
Rh immune globulin N/A N/A N/A N/A 0 0
aN/A = not available; trace = < 1 ,ug/mL; n = 4 for each product.
alsofoundinfibrinogen andimmunoglobulins withhigher
levels in albumin (23).
The study carried out in our laboratory compared
MEHP and DEHPincommerciallyavailable plasmafrac-
tionation products obtained from three different North
American companies and related the level ofthe contam-
ination to the conditions of plasma storage and trans-
portation (Table 2). Asmightbe expected, contamination
ofplasma with DEHP and MEHP resulted in a concom-
itant contamination of blood products prepared by frac-
tionation ofthis plasma. Products from companies A and
B, which used fresh frozen plasma as starting material,
did not contain DEHP but did have low levels of MEHP
in all of the albumin-containing fractions, as well as in
some Factor VIII preparations. On the other hand, the
25% NSA from company C, which used out-dated un-
frozen plasma as starting material, was contaminated by
high levels of MEHP but no DEHP, while Factor IX
preparations contained both MEHP and DEHP
These data showed a direct correlation between tem-
perature of storage or shipment of plasma and the level
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FIGURE 3. DEHP and MEHP levels in PPP stored at -30°C. Levels
of DEHP and MEHP in PPP stored at -30°C: (A,O) frozen in
glass tubes; (A,O) frozen in PVC bags; (LI,) bags pooled and
frozen.
of contaminating phthalates. Since we have shown that
the enzyme with DEHP hydrolyzing activity copurifies
with albumin, even after Affi-gel Blue chromatography,
it is not surprising that MEHP was present in all NSA
and plasma protein fraction solutions. The MEHP, once
formed, is tightly bound to albumin in the purified prep-
aration and could not be removed by dialysis or ultra-
centrifugation. By freezing the plasma it was possible to
prevent further leaching of DEHP or conversion to
MEHP (Fig. 3) for 6 months. DEHP does not increase
in frozen RCC stored for up to 2 years (5) or in plasma
which is frozen for 5 weeks (23).
The recommendation that was made at the time ofthis
study (1981) was to freeze out-dated plasma to be used
for fractionation as soon as possible prior to shipment to
the fractionator. Unfortunately, this still is not currently
the practice in several countries. A few months ago, we
did a study in our Centre for a hospital which was rou-
tinely storing a liter of lactated Ringer's solution with
albumin for 3 months in PVC bags. The DEHP levels
slowly increased during this period; however, the initial
level of MEHP in the 25% stock NSA solution used for
the preparation of the IV solution was extremely high
(300 ,ug/mL). The enzyme which converts DEHP to
MEHPcopurified withthe albumin, and theMEHP, once
formed in the plasma, bound to the albumin during pu-
rification. Immediate freezing of the out-dated plasma
would eliminate both of these effects.
Despite the availability ofnon-DEHPplasticizedbags,
the collection and storage ofRCCs is still done in DEHP
plasticizedpacksforanextendedperiod (35days) oftime.
Recently, we have examined the interaction of DEHP
Table 3. Association of "4C-DEHP with red blood cells.
Association after storage at 4°C, %V
Samples No storage 7 days storage
Red cell concentrate 100.0 ± 0* 100.0 ± 0
before washing
Wash supernatant 35.9 ± 1.6b 47.9 ± 4.6c
Platelet pellet from 6.3 ± 2.0 10.0 ± 3.4
wash
Washed RBC 28.0 ± 2.4d 24.6 ± 5.5e
RBC cytosol 14.7 ± 0.8 13.0 ± 0.8
RBC membrane 11.6 ± 1.2 11.7 ± 2.0
aMean + SD (n = 4)
b,csignificantly different at p <0.05.
d,enotsignificantlydifferent atp <0.05 (unpaired Student's T-test).
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with stored RCC (11) and found that 14C-DEHP is in-
corporated into the RBC during storage at 4°C. There
is an immediate binding of 28% of the available 14C-
DEHP to the RBC on day 0, with approximately equal
amounts of14C-DEHPbeingincorporatedintothecytosol
and membrane fractions (Table 3). The total amount and
relative distribution of the 14C-DEHP does not signifi-
cantly change over 7 days. A study by Estep et al. (24)
showed that distribution of DEHP added as an emulsion
to whole blood was complete within 24 hr. They found
that about 5 to 10% of the total blood concentration of
DEHP was associated with RBC; however, the DEHP
concentration they were workingwith was 300 to 500 jig/
mL, whereas ours was 50 ,ug/mL. The significant point
of this work is that the stability of RBC is greatly im-
proved by the addition of DEHP
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FIGURE 4. Reduced osmotic fragility of red blood cells. Red cells
concentrates (A) contained DEHP-enriched plasma and were stored
in polyolefin bags; (B) contained fresh plasma in polyolefin bags; (C)
contained fresh plasma in PVC bags (n = 3). Red cell concentrates
were prepared by adding either fresh plasma or DEHP enriched
plasma to packed RBCs. Red cell osmotic fragility was determined
on days 0, 21, and 35.
We have found increased osmotic fragility in RCC
stored in polyolefin bags rather than in PVC bags, with
significant release ofhemoglobin after prolonged storage
ofcellsinpolyolefinbags(Fig. 4). WhenRBCwerestored
in DEHP-enriched plasma in polyolefin bags (series A)
orin PVCbags (series C), the stability was considerably
better than for RBC stored in polyolefin bags without
the DEHP (series B). Thedecreased RBCfragility could
be correlated directly to the DEHP concentration which
in series A was 97.2 ,ug/mL, series B 30.0 ,ug/mL, and
series C34.2 p.g/mL. Byday35, the DEHPconcentration
in the series C cells was 418.3 ,ig/mL.
The values for plasma hemoglobin in the series A, B,
and C RCC storage groups agreed withthe osmoticfrag-
ility studies, i.e., there was less hemoglobin in series C
(stored in PVC packs) than in either of the two RCC
stored in polyolefin packs (Table 4). The series A samples
hadthehighestinitialconcentration ofDEHPandshowed
the lowest plasma hemoglobin on day 0.
There was also decreased osmotic fragility in cell con-
centrates stored in glass tubes with added DEHP The
level of DEHP was 50.8 ,ug/mL on day 0 and 40 ,ug/mL
onday21. Therewasnodetectable DEHPinthecontrols.
Estep et al. (24) were able to show a 20-fold improve-
ment in the percentage of cells exhibiting normal mor-
phology, a 60% inhibition in the accumulation of hemo-
globin in plasma, a 50% reduction in the degree of
erythrocyte microvesiculation, and an enhanced preser-
vationofnormalcellularosmoticfragility andfilterability
after 35 days of refrigerated storage when DEHP was
added to the environment.
Two important conclusions can be drawn: one is that
previous estimates of the dose of plasticizers which pa-
tients receive have probably been underestimated, since
the calculations were based primarily on plasma concen-
trations, ignoring the uptake by RBC; the other conclu-
sion has been observed by other groups (24,25) as well
as ourselves, that in vitro stability of RCC is improved
by exposure to DEHP
Although PVC bags are still used for storage ofRBC,
platelets are now being stored in new bags which allow
5 day storage. When platelets were kept in PVC bags,
Table 4. Plasma hemoglobin values of stored red cell
concentrates.
Plasma hemoglobin, mg/dLb Red cell concentrates' Da a 1 Dy3 Day 0 Day 21 Day 35
A Prepared with DEHP 5.7 ± 2.0 30.3 ± 3.1 118.3 ± 38.5
plasma, stored in po-
lyolefin packs
B Prepared with fresh 26.7 ± 3.6 73.3 ± 13.4 181.7 ± 70.6
plasma, stored in po-
lyolefin packs
C Prepared with fresh 21.2 ± 6.5 42.3 ± 8.4 90.3 ± 20.8
plasma, stored in
PVC packs
aThe red cell concentrates were prepared from pooled RBCs and
stored at 4°C. Immediately prior to assay they were diluted to a
hematocrit of 40% with fresh plasma.
bMean ± SD (n = 3).
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they progressively lost functional integrity and were not
used after 3 days. We have found that DEHP leaches
from PVC bags into PC (6) and that the platelets bind
6 to 10% of "C-DEHP mixed with whole blood. In a
recent study in our laboratory, the direct effect of the
plasticizer DEHP on platelet phospholipa&e A2 (PLA2)
activity was studied. PLA2 activity decreased contin-
ually during storage over 3 days in DEHP-containing
bagsto61%oftheactivityonthedayofcollection. During
this period DEHP levels increased from 35 to 270 ,ug/
mL. Addition ofDEHP directly to fresh platelets at con-
centrations of 67 ,ug/mL or higher resulted in a similar
drop of PLA2 activity to 53% of control. The inhibition
of PLA2 in platelets by accumulated DEHP would pre-
vent arachidonic acid liberation and endoperoxide for-
mation, rendering platelets unable to respond to phys-
iological stimuli in vitro and in vivo (12).
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FIGURE 6. Day6ratio of"DEHP:MEHP-like"leachables: (0)DEHP
extraction procedure and HPLC system; (U) MEHP extraction
procedure and HPLC system.
While it would seem that this problem is now solved
by the storage of platelets in the new plastic bags, we
have recently found that there is a significant level of
leaching of bag-derived compounds into PC, PRP, or
plasmawhen these fractions are stored inthe Fenwal PL
732 at 22°C in a platelet rotator (13). Although stated by
the manufacturer to be essentially free of liquid plasti-
cizers, an antioxidant, 1,3,5-trimethyl-2,4,6-tris-(3,5-di-
tert-butyl-4-hydroxybenzyl)benzene (BHBB), is used in
the manufacture ofthe polyolefin plastic.
The major leachable compound observed has the same
HPLC retention time as does DEHP This compound can
be extracted from the bag itself, in addition to a small
amount ofBHBB. The ratio ofBHBB to the major leach-
able compound is 1:15; BHBB was not detected in the
extract from any ofthe stored platelet fractions or from
plasma (Fig. 5).
The amount ofleachable materialcontinued toincrease
linearly up to 72 hr storage. On day 6, the ratio of the
twoleachable compoundsinPRPsupernatant andplasma
was determined. By using the extraction method for
DEHP and MEHP (6), followed by analysis of the ex-
tracts using the HPLC system for DEHP and MEHP
(9), it canbe seeninFigure6thattheratio ofcompounds
is 3:1 whether the fraction analyzed is PRP or plasma.
The recent observation of aberrant morphology of
platelets following storage in these new bags may be due
to these leachable compounds or to other factors associ-
ated withpolyolefinbags. Fratantoni et al. (14) were able
to stop the development ofthe unusual morphological al-
terations ifthe permeability ofthe container was inhib-
itedandthepHkeptbelow6.7. Inlightofthedocumented
effect of DEHP on red cell membranes, it may perhaps
be the absence ofhigh levels ofDEHP whichpermits the
platelet membrane to change shape.
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Conclusions
As is usually the case with any technological advance,
the development of flexible plastic bags, multiple blood
pack systems, and plastic tubing for medical use has
brought with it great benefits along with some risk. It
is well established that DEHP leaches out ofthese bags
and other medical devices into blood components, that
theconcentrationincreaseswithstorage, andthatDEHP
is converted to MEHP, a more toxic metabolite (1-6).
Animalstudieshavedemonstratedthetoxicity ofthese
compounds and more recently their carcinogenicity and
teratogenicity (16). Although the results of these inves-
tigations cannot be extrapolated directly to humans,
DEHP and MEHP have been found in blood products
such as albumin and cryoprecipitate and have been iden-
tified in the sera and tissues of many patients (8). This
has raised concerns about the amount of plasticizer re-
ceived by hemodialysis patients, hemophiliacs, and other
multi-transfused individuals. Non-DEHP plastics, such
as polyolefin, are now available and are used for storing
platelets, but these plastics are not generally used for
RC storage.
The data we obtained on the binding of 14C-DEHP to
the red cell membrane suggest that the previous esti-
mates of the dose of plasticizers which patients receive
have been underestimated, since the calculations were
based primarily on plasma concentrations, ignoring the
uptake by the red cell. This difference has important
implications, since it is RCC rather than whole blood
which are stored in the majority of blood banks. Long-
term storage in the absence of DEHP severely compro-
mises red cell integrity and survival (11).
Platelets which were previously stored for 3 days in
DEHP-containingPVCpacks arenowstoredinpolyolefin
bags where they are stable for 5 days; however, we have
found that material also leaches from these bags (13);
othergroupshavereportedaberrantmorphologyofplate-
lets stored in these bags (14).
In order to assess the risk/benefit question for blood
andbloodproducts stored inplastic containers, themech-
anism ofinteraction ofthe plasticizer with the RBC and
platelet membrane must be fully defined, as well as the
effects on RBC and platelet metabolism.
This work was supported by a N.H.R.D.P grant.
REFERENCES
1. Valeri, C. R., Contreras, T. J., Feingold, H., Sheibley, R. H., and
Jaeger, R. J. Accumulation ofdi-2-ethylhexyl phthalate (DEHP) in
whole blood, platelet concentrates, and platelet-poor plasma. I.
Effect ofDEHP on platelet survival and function. Environ. Health
Perspect. 3: 103-118 (1973).
2. Marcel, Y. L., and Noel, S. P Contamination of blood stored in
plastic packs. Lancet 1: 35-36 (1970).
3. Jaeger, R. J., and Rubin, R. J. Di-2-ethylhexyl phthalate: a plas-
ticizer contaminant ofplatelet concentrates. Transfusion 13: 107-
108 (1973).
4. Peck, C. C., Odom, D. G., Friedman, H. I., Albro, P W, Hass,
J. R., Brady, J. T., and Jess, D. A. Di-2-ethylhexyl phthalate
(DEHP) and mono-2-ethylhexyl phthalate (MEHP) accumulation
in whole blood and red cell concentrates. Transfusion 19: 137-146
(1979).
5. Contreras, T. J., Sheibley, R. H., and Valeri, C. R. Accumulation
of di-2-ethylhexyl phthalate (DEHP) in whole blood, platelet con-
centrate, and platelet-poor plasma. Transfusion 14: 34-46 (1974).
6. Rock, G. A., Secours, V E., Franklin, C. A., Chu, I., and Vil-
leneuve, D. C. The accumulation of mono-2-ethylhexyl phthalate
(MEHP) during storage of whole blood and plasma. Transfusion
18: 553-558 (1978).
7. Guess, W L., Jacob, J., and Autian, J. A studyofpolyvinyl chloride
blood bag assemblies. I. Alteration of contamination of ACD so-
lutions. J. Drug Intell. 1: 120-122 (1967).
8. Jaeger, R. J., and Rubin, R. J. Plasticizers from plastic devices.
Extraction, metabolism and accumulation by biological systems.
Science 170: 460-462 (1970).
9. Cole, R. S., Tocchi, M., Wye, E., Villeneuve, D. C., and Rock, G.
Contamination of commercial blood products by di-(2-ethylhexyl)
phthalate andmono-(2-ethylhexyl) phthalate. Vox Sang40: 317-322
(1981).
10. Chu, I., Villeneuve, D. C., Secours, V, Franklin, C., Rock, G.,
and Viau, A. Metabolism and tissue distribution ofmono-(2-ethyl-
hexyl) phthalate inthe rat. DrugMetab. Dispos. 6: 146-149 (1978).
11. Rock, G., Tocchi, M., Ganz, P R., and Tackaberry, E. S. Incor-
poration of plasticizer into red cells during storage. Transfusion
24: 493-498 (1984).
12. Adams, G. A., Chan, A. C., and Rock, G. A. The plasticizer in
blood bags inhibits platelet phospholipase A2 (abstr.). Can. Fed.
Biol. Sci., Ottawa, Canada, June 1983.
13. Labow, R. S., Tocchi, M., and Rock, G. A leachable material from
polyolefin bags (abstr.). Presented at 20th International Society
Blood Transfusion, Munich, July 1984.
14. Fratantoni, J. C., Sturdivant, B., and Poindexter, B. J. Aberrant
morphology ofplatelets stored infive daycontainers. Thromb. Res.
33: 607-615 (1984).
15. Lawrence, W H. Phthalate esters: the question of safety Clin.
Toxicol. 13(1): 89-139 (1978).
16. Kluwe, W M., McConnell, E. E., Huff, J. E., Haseman, J. K.,
Douglas, J. F, and Hartwell, W V Carcinogenicity testing of
phthalate esters and related compounds bythe National Toxicology
Programand National Cancer Institute. Environ. HealthPFrspect.
45: 129-133 (1982).
17. Rock, G. A., Farrah, G., Rozon, G., Smiley, R. K., Cole, R., Vil-
leneuve, D., and Tittley, P Analysis ofcontaminants in Factor VIII
preparations administered to patients with hemophilia. Can. Med.
Assoc. J. 128: 403-408 (1983).
18. Lewis, L. M., Flechtner, T. WV, Kerkay, J., Pearson, K. H., and
Nakamoto, S. Bis(2-ethylhexyl) phthalate concentrations in the
serum ofhemodialysis patients. Clin. Chem. 24: 741-746 (1978).
19. Cole, R., Tocchi, M., Posen, G., Smiley, R. K., Villeneuve, D. C.,
and Rock, G. Blood levels of plasticizers in hemophiliacs and he-
modialysis patients: the multi-transfused patient (abstr.). Pre-
sentedto InternationalSocietyofHematology International Society
of Blood Transfusion, Montreal, August 1980.
20. Cole, R. S., Tocchi, M., Franklin, C. A., Villeneuve, D. C., and
Rock, G. The enzymatic conversion of DEHP to MEHP in human
plasma. (abstr.). Presented at XI International Congress of Bio-
chemistry, 1979.
21. Cole, R. S., Tocchi, M., Franklin, C., Villeneuve, D. C., and Rock,
G. Effect ofadenine on the contamination ofstored blood by di-(2-
ethylhexyl) phthalate and mono-(2-ethylhexyl) phthalate (abstr.).
Presented to American Association of Blood Banks, Las Vegas,
October 1979.
22. Gilbo, C. M., and Coles, N. W Di(2-ethylhexyl) phthalate content
of plasma fractions prepared by low temperature ethanol (Cohn)
fractionation. Vox Sang 29: 242-247 (1975).
23. Vessman, J., and Rietz, G. Formation ofmono(ethylhexyl) phthal-
ate from di(ethylhexyl) phthalate in human plasma stored in PVC
bags and its presence in fractionated plasma proteins. Vox Sang
35: 75-80 (1978).
24. Estep, T. N., Miller, T. J., Andrews, R. A., and Stupar, K. R.
Interaction ofdi-(2-ethylhexyl) phthalatewiththeerythrocyte: dis-316 ROCK, LABOW, AND TOCCHI
tribution and influence on cellular integrity during the storage of
whole blood (abstract). Blood 6: 1270-1276 (1984).
25. Stern, I. J., and Carmen, R. A. Hemolysis in stored blood: sta-
bilizing effect ofphthalate plasticizer (abstr.). Presented at Inter-
national Society of Hematology/International Society of Blood
Transfusion, Montreal, August 1980.